Skip to content
RESEARCH USE ONLYFor research purposes onlyMÉXICO
Peptides MEX

Peptides MEX / Comparisons

Ipamorelin vs CJC-1295: receptors and GH response

Both have been investigated for stimulating growth hormone, but start from different designs and receptor pathways. Ipamorelin is a pentapeptide in the GHRP secretagogue family; CJC-1295 is a GHRH analogue whose identity requires the DAC distinction.

Updated · Sources and editorial standards

Key differences: Ipamorelin / CJC-1295
FeatureIpamorelinCJC-1295
Molecular design[1][2]Secretagogue pentapeptideGHRH analogue; DAC distinction required
Described pathway[1][2]GHRP-type receptorGHRH pathway
Featured human measurement[3][4]Peptide and GH concentrationsGH and IGF-I with long-acting analogue

A shared hormonal response does not imply a shared receptor

The original ipamorelin study used antagonists to attribute GH release to a GHRP-type receptor. CJC-1295 was designed from GHRH. Two stimuli can converge on pituitary GH secretion without representing the same molecular signal or having the same time course.

Sources: [1][2]

What volunteer studies contributed

The human ipamorelin study related peptide concentrations to the GH response to build a pharmacokinetic and pharmacodynamic model. Trials of long-acting CJC-1295 measured GH and IGF-I in healthy adults. These are physiology and exposure studies with different designs, not a comparative test of muscle gain.

Sources: [3][4]

Specifying DAC changes the comparison

Albumin-binding capability belongs to the DAC form described in the technical review. A CJC-1295 without-DAC label does not justify transferring results from the long-acting analogue. Interpreting a comparison with ipamorelin first requires identifying which CJC entity the study examined.

Sources: [2][4]

Questions about this reference

Are they two forms of growth hormone?

No. The studies investigate them as stimuli for GH secretion. The measured hormone is a system response, rather than the chemical identity of ipamorelin or CJC-1295.

[1][4]

Do individual studies validate a mixture of both?

No. These trials do not establish the composition, stability or outcome of a commercial mixture. Distinct pathways can motivate a hypothesis, but do not demonstrate a beneficial interaction.

[3][4]

Sources and original reading

  1. Ipamorelin, the first selective growth hormone secretagogue
  2. FDA briefing: CJC-1295-related bulk drug substances, December 2024
  3. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
  4. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults

Content updated: . How this content is prepared and checked.

Links for comparing concepts and identities; they do not indicate equivalence or combinations for use.